TITLE
Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2

SUMMARY
Analysis of endocrine-resistant LY2 breast cancer cells depleted of p160 steroid coactivator protein SRC-1 and treated with tamoxifen. SRC-1 is central to the development of the endocrine resistant phenotype. Results provide insight into the molecular basis of endocrine resistant breast cancer.

ORGANISM
Homo sapiens

PLATFORM
GPL570 : [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

CITATIONS
McCartan D, Bolger JC, Fagan A, Byrne C et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012 Jan 1;72(1):220-9. PMID:  22072566 Walsh CA, Bolger JC, Byrne C, Cocchiglia S et al. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res 2014 May 1;74(9):2533-44. PMID:  24648347

